Cellular immune response to the anti-SARS-CoV-2 BNT162b2 mRNA vaccine in pediatric autoimmune inflammatory rheumatic disease patients and controls.

Cellular immune response to the anti-SARS-CoV-2 BNT162b2 mRNA vaccine in pediatric autoimmune inflammatory rheumatic disease patients and controls.

Publication date: Jul 12, 2024

This paper aims to compare the cellular immune response to the SARS-CoV-2 BNT162b2 vaccine of pediatric patients with autoimmune inflammatory rheumatic disease (pAIIRD) and healthy controls. A prospective longitudinal study was conducted between April 2021 and December 2022 at the Tel Aviv Medical Center. Children

Concepts Keywords
April Adolescent
Bnt162b2 Antibodies, Viral
Healthy Antibodies, Viral
Rheumatic Autoimmune Diseases
Vaccine BNT162 Vaccine
BNT162 Vaccine
BNT162b2 vaccine
CD4-Positive T-Lymphocytes
cellular immunity
Child
COVID-19
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Female
Humans
humoral immunity
Immunity, Cellular
Immunity, Humoral
Interferon-gamma
Interferon-gamma
juvenile arthritis
Longitudinal Studies
Male
Prospective Studies
Rheumatic Diseases
rheumatic diseases
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus

Semantics

Type Source Name
disease VO vaccine
disease MESH rheumatic disease
disease MESH Autoimmune Diseases
disease MESH COVID-19
disease MESH juvenile arthritis
disease VO Glycoprotein

Original Article

(Visited 2 times, 1 visits today)